Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Blood (2023) 142 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2023-178551

Published: 2023

Journal Articles

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Takashi Watanabe, Kensei Tobinai, Ｍasashi Wakabayashi, Dai Maruyama, Kazuhito Yamamoto, Nobuko Kubota, Kazuyuki Shimada, Kohsuke Asagoe, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 3615–3617.

https://doi.org/10.1182/blood-2022-159967

Published: 2022

Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-135999

Published: 2020

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli

Blood (2018) 132 (Supplement 1): 783.

https://doi.org/10.1182/blood-2018-99-116845

Published: 2018

Journal Articles

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Blood (2018) 132 (Supplement 1): 4194.

https://doi.org/10.1182/blood-2018-99-110201

Published: 2018

Journal Articles

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Blood (2018) 132 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2018-99-110334

Published: 2018

Journal Articles

Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results

Won-Seog Kim, MD PhD, Christian Buske, MD, Larry W Kwak, MD PhD, Michinori Ogura, MDPhD, Bertrand Coiffier, MD PhD, SangJoon Lee, PhD, SuYoung Kim

Blood (2018) 132 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2018-99-112716

Published: 2018

Journal Articles

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Michinori Ogura, MD PhD, Ken Ohmachi, MD, Ritsuro Suzuki, MD PhD, Yoshiko Atsuta, MD PhD, Tatsuya Ito, MD, Kazuma Ohyashiki, MD, Shingo Yano, MD PhD, Michihiro Hidaka, MD PhD, Kiyoshi Ando, MD PhD, Noriko Fukuhara, MD PhD, Yoshihisa Morishita, MD PhD, Takayo Suzuki, MD PhD, Kunihiro Tsukasaki, MD PhD, Naoki Kobayashi, MD PhD, Kenji Tsukamoto, MD, Yukiyasu Ozawa, MD PhD, Tomomitsu Hotta, MD PhD, Tomohiro Kinoshita, MD PhD

Blood (2017) 130 (Supplement 1): 2789.

https://doi.org/10.1182/blood.V130.Suppl_1.2789.2789

Published: 2017

Journal Articles

Ten-Year Follow-up of Newly Diagnosed Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) As First-Line Therapy in JCOG0203 Trial

Takashi Watanabe, MDPhD, Kensei Tobinai, MD, PhD, Masashi Wakabayashi, MSc, Yasuo Morishima, MDPhD, Hirobumi Kobayashi, MD PhD, Tomohiro Kinoshita, MD PhD, Takayo Suzuki, MD PhD, Motoko Yamaguchi, MDPhD, Kiyoshi Ando, MD PhD, Michinori Ogura, MD PhD, Masafumi Taniwaki, MD PhD, Naokuni Uike, MD, PhD, Tadashi Yoshino, MD PhD, Shigeru Nawano, MD PhD, Takashi Terauchi, MD PhD, Tomomitsu Hotta, MD PhD, Kunihiro Tsukasaki, MD PhD

Blood (2017) 130 (Supplement 1): 5168.

https://doi.org/10.1182/blood.V130.Suppl_1.5168.5168

Published: 2017

Journal Articles

Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma

Won Seog Kim, MD, Ph. D., Bertrand Coiffier, MD PhD, Christian Buske, MD, Michinori Ogura, MD PhD, Larry W Kwak, MDPhD, SangJoon Lee, YunJu Bae, SuYoung Kim, MinJu Kim, SangMi Lee, DaHye Kwak, HyunJin Lee

Blood (2017) 130 (Supplement 1): 1504.

https://doi.org/10.1182/blood.V130.Suppl_1.1504.1504

Published: 2017

Journal Articles

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Blood (2016) 128 (22): 3012.

https://doi.org/10.1182/blood.V128.22.3012.3012

Published: 2016

Journal Articles

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Aliaksandr Prokharau, Mamia Zodelava, Dzhelil Osmanov, Michinori Ogura, Christian Buske, Larry Kwak, Sang Joon Lee, Sung Young Lee, Yun Ju Bae, Won Seog Kim

Blood (2016) 128 (22): 1807.

https://doi.org/10.1182/blood.V128.22.1807.1807

Published: 2016

Journal Articles

Limited-Stage Mantle Cell Lymphoma

Ritsuro Suzuki, MD PhD, Dai Chihara, MD PhD, Naoko Asano, MD PhD, Ken Ohmachi, MD, Tomohiro Kinoshita, MD PhD, Kosei Matsue, MD PhD, Junji Suzumiya, MD PhD, Michinori Ogura

Blood (2016) 128 (22): 5330.

https://doi.org/10.1182/blood.V128.22.5330.5330

Published: 2016

Journal Articles

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

Michinori Ogura, Yukio Kobayashi, MD PhD, Shiro Kubonishi, MD PhD, Michihiro Hidaka, MD PhD, Toshiki Uchida, MD PhD, Yasushi Takamatsu, MD PhD

Blood (2016) 128 (22): 5549.

https://doi.org/10.1182/blood.V128.22.5549.5549

Published: 2016

Journal Articles

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Dai Maruyama, MD PhD, Kensei Tobinai, MD PhD, Kiyoshi Ando, MD PhD, Ken Ohmachi, MD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Tadashi Nakanishi, Masayuki Namiki, PhD

Blood (2015) 126 (23): 2724.

https://doi.org/10.1182/blood.V126.23.2724.2724

Published: 2015

Journal Articles

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Hiroshi Fujiwara, MD PhD, Takashi Ishida, MD PhD, Kisato Nosaka, MD PhD, Naoya Taira, MD, Yasunobu Abe, MD PhD, Yoshitaka Imaizumi, MD PhD, Yukiyoshi Moriuchi, MD, Tatsuro Jo, MD PhD, Kenichi Ishizawa, MD, PhD, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Shigeki Ito, MD PhD, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, MD, Shuichi Midorikawa, PhD, Wanda Ruiz, PhD, Tomoko Ohtsu, MD

Blood (2015) 126 (23): 181.

https://doi.org/10.1182/blood.V126.23.181.181

Published: 2015

Journal Articles

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

Won Seog Kim, Michinori Ogura, Christian Buske, Bertrand Coiffier, Juan-Manuel Sancho, Wojciech Jurczak, Jin Seok Kim, Raj V Nagarkar, Edvard Zhavrid, Jose Angel Hernandez Rivas, Yuriy Vinnyk, Panagiotis Tsirigotis, Piera Viero, Elena Volodicheva, Samuel Fourie, Juan Soler

Blood (2015) 126 (23): 5111.

https://doi.org/10.1182/blood.V126.23.5111.5111

Published: 2015

Journal Articles

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Takahiro Suzuki, MD PhD, Yasunori Ueda, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Keiya Ozawa, MD PhD, Shigesaburo Miyakoshi, MDPhD, Tomoki Naoe, MD PhD, Makoto Murata, MD PhD, Masahiro Kizaki, MD PhD, Naokuni Uike, MD, Yasunobu Abe, MD PhD, Michihiro Hidaka, MD PhD, Shuzo Tagashira, Satoru Tsuchiya, Kazuma Ohyashiki, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2015) 126 (23): 2868.

https://doi.org/10.1182/blood.V126.23.2868.2868

Published: 2015

Journal Articles

Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Naokuni Uike, MD, PhD, Yasunobu Abe, MD PhD, Kenichi Ishizawa, MD, PhD, Yoko Okitsu, MD PhD, Kensei Tobinai, MD PhD, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, MD PhD

Blood (2015) 126 (23): 2714.

https://doi.org/10.1182/blood.V126.23.2714.2714

Published: 2015

NARROW

Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601

Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601

Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study

Similar Efficacy and Safety of CT-P10 and Reference Rituximab in Patients with Advanced Stage Follicular Lymphoma: Updated Phase III Study Results

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Ten-Year Follow-up of Newly Diagnosed Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) As First-Line Therapy in JCOG0203 Trial

Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL)

Limited-Stage Mantle Cell Lymphoma

Safety, Efficacy, and Pharmacokinetic Profiles of Intravenous Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory Myelodysplastic Syndromes: A Multicenter, Open-Label Phase I Clinical Study

Phase I Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL)

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only